Online citations, reference lists, and bibliographies.
← Back to Search

Treatment Of Resistant Severe Psoriasis With Systemic Cyclosporine.

D. D. Picascia, J. Garden, R. Freinkel, H. Roenigk
Published 1987 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Four patients with severe psoriasis have been treated with oral cyclosporine for 6 months. Two had generalized erythroderma and two had extensive plaque-type psoriasis; all had either become unresponsive to or were unable to use other accepted treatments. All four patients responded rapidly and were completely clear of psoriasis within 3 weeks of beginning therapy. Initial doses ranged from 7.5 to 8.5 mg/kg/day. Mild reversible nephrotoxicity occurred in the one patient whose cyclosporine trough level briefly exceeded 200 ng/ml. Cyclosporine may offer an alternative therapeutic modality in the management of erythrodermic or severe resistant plaque-type psoriasis. The effectiveness of cyclosporine in psoriasis underscores the putative role of cell-mediated immune factors in the pathogenesis of psoriasis.
This paper references
10.1111/1523-1747.EP12494600
Impaired antigen-specific suppressor cell activity in psoriasis and psoriatic arthritis.
D. Gladman (1981)
10.1001/JAMA.1986.03380220076026
Cyclosporine improves psoriasis in a double-blind study.
C. Ellis (1986)
10.1111/1523-1747.EP12541239
Defective function of T lymphocytes in psoriasis.
W. Gliński (1978)
Immunological aspects of psoriasis. I. Immunoglobulins and anti-IgG factors.
Jean-Jacques Guilhou (1976)
10.1016/0002-9343(84)90356-5
Side effects of systemic cyclosporine in patients not undergoing transplantation.
A. Palestine (1984)
10.1016/S0190-9622(87)70010-3
Skin tumors in the European PUVA Study
T. Henseler (1987)
10.1007/BF00408236
Immunopathology of psoriasis
R. Cormane (2004)
The impact of cyclosporine therapy on the occurrence of infection in the renal transplant recipient.
N. Tolkoff-Rubin (1986)
10.1111/j.1365-2133.1976.tb07017.x
Immunological aspects of psoriasis
J. Guilhou (1976)
10.1097/00007890-198408000-00001
Sparing of suppressor cells: a critical action of cyclosporine.
J. Kupiec-Weglinski (1984)
10.1097/00007890-198309000-00007
Early infections in kidney, heart, and liver transplant recipients on cyclosporine.
J. Dummer (1983)
10.1136/bmj.293.6549.731
Clearance of psoriasis with low dose cyclosporin.
C. E. Griffiths (1986)
10.1056/NEJM197904123001501
Risk of cutaneous carcinoma in patients treated with oral methoxsalen photochemotherapy for psoriasis.
R. Stern (1979)
10.1111/j.1365-3083.1973.tb02015.x
Antibodies in Psoriatic Scales
H. Krogh (1973)
10.1159/000230762
Antibodies in human sera to stratum corneum.
H. Krogh (1969)
10.1001/ARCHDERM.1982.01650240010011
Increased helper-suppressor T-cell ratio in psoriasis.
D. J. Ligresti (1982)
10.1016/S0140-6736(85)91101-8
CYCLOSPORIN AND PSORIASIS
J. P. Hooff (1985)
10.1159/000249288
Cutaneous lesions in 67 cyclosporin-treated renal transplant recipients.
P. Bencini (1986)
10.1016/S0140-6736(84)91194-2
CYCLOSPORIN FOR PSORIASIS
J. Harper (1984)
10.1111/j.1365-2133.1986.tb05727.x
Cyclopsorin A and psoriasis
B. Monk (1986)
Histiocytic Lymphoma in Renal Transplant Patients Receiving Cyclosporine.
J. Rosenthal (1983)
10.1056/NEJM197909063011016
Cyclosporin A for psoriasis.
W. Müller (1979)
10.1111/j.1365-2133.1984.tb07309.x
T‐cell subpopulations in the blood and skin of patients with psoriasis
B. Baker (1984)
10.1093/INFDIS/149.2.143
Pneumocystis carinii pneumonia in renal-transplant recipients treated with cyclosporine and steroids.
A. M. Hardy (1984)
10.1111/j.1365-2133.1976.tb05137.x
Immunological aspects of psoriasis
J. Guilhou (1976)
10.1016/S0190-9622(81)70096-3
Normal numbers of phenotypic helper, suppressor, and total T cell populations in psoriasis vulgaris: quantitation by monoclonal antibodies.
W. DePietro (1981)
10.1111/j.1365-2133.1969.tb15986.x
IMMUNOGLOBULINES IN DERMATITIS HERPETIFORMIS AND VARIOUS OTHER SKIN DISEASES
N. G. Fraser (1969)
10.1126/SCIENCE.6334364
Induction of interleukin 2 messenger RNA inhibited by cyclosporin A.
J. Elliott (1984)
10.1016/0090-1229(78)90135-6
Evaluation of lymphocyte subpopulations and T-cell functions in psoriasis.
J. Clot (1978)
10.1111/1523-1747.EP12507392
Immunological aspects of psoriasis: V. T. cell subsets and suppressor cell functions regulating immune responses in peripheral blood.
J. Clot (1982)
10.1001/ARCHDERM.1980.01640250053015
Suppressor cell function in psoriasis.
D. N. Suader (1980)
10.1002/EJI.1830110812
Cyclosporin A mediates immunosuppression of primary cytotoxic T cell responses by impairing the release of interleukin 1 and interleukin 2
D. Bunjes (1981)
10.1111/1523-1747.EP12522898
Suppressor function of peripheral blood mononuclear cells in patients with psoriasis vulgaris.
J. Hunyadi (1980)
10.1001/ARCHDERM.1986.01660210078022
Dermatologic applications of cyclosporine.
C. A. Biren (1986)
10.1136/BMJ.293.6545.509
Cannulation of difficult oesophageal strictures with angiographic catheters
G. Hartnell (1986)
Development and incidence of cancer following cyclosporine therapy.
I. Penn (1986)
10.1056/NEJM198607103150207
Psoriasis and Raynaud's phenomenon associated with autoantibodies to U1 and U2 small nuclear ribonucleoproteins.
W. Reeves (1986)
10.1111/j.1365-2133.1986.tb04070.x
Short‐term use of cyclosporin A in severe psoriasis
T. Joost (1986)



This paper is referenced by
10.1007/978-1-4899-1167-4
Immunopharmacology in Autoimmune Diseases and Transplantation
H. Rugstad (1992)
10.1016/0738-081X(91)90081-U
Cyclosporine A in psoriasis.
A. Rebora (1991)
10.1001/ARCHDERM.1996.03890260117017
Psoriatic arthritis. New types, new treatments.
T. Ruzicka (1996)
10.1201/9780203912683.CH7
Cyclosporine in the Treatment of Severe Psoriasis
C. Ellis (2003)
10.1007/978-3-7643-7724-3_7
Traditional systemic therapy I: methotrexate and cyclosporine
Edward Prodanovic (2008)
10.3109/9781420088687-9
Therapy of Moderate-to-Severe Psoriasis with Methotrexate
G. Weinstein (2008)
10.1007/978-3-662-00181-3_68
Systemic Treatment of Dermatoses
O. Braun-Falco (1991)
10.1111/j.1365-4362.1994.tb01533.x
CYCLOSPORINE IN DERMATOLOGY: PHARMACOLOGY AND CLINICAL USE
A. Kauvar (1994)
10.1016/0190-9622(92)70224-4
Differential effects of cyclosporine and etretinate on serum cytokine levels in patients with psoriasis.
T. Shiohara (1992)
10.11340/SKINRESEARCH1959.33.207
Treatment of Severe Psoriasis Vulgaris with Cyclosporin Soft Gelatine Capsule
Mari Higashiyama (1991)
10.1007/s00441-008-0629-1
Interleukin-6 counteracts effects of cyclosporin A on extracellular matrix metabolism by human dermal fibroblasts
M. Abe (2008)
10.1067/MJD.2000.101596
Sex-specific differences in the treatment of severe psoriasis.
R. Hotard (2000)
10.1111/j.1346-8138.1988.tb01195.x
Treatment of Severe Psoriasis with Low Dose Cyclosporin A and the Effect on the Helper‐suppressor T Cell Ratio in Peripheral Blood
T. Sasaki (1988)
10.1111/J.1365-2230.1991.TB00412.X
Facial and eyelid psoriasis after cyclosporin withdrawal
J. Bernhard (1991)
10.2336/NISHINIHONHIFU.53.583
Clinical efficacy of cyclosporin soft gelatine capsule for severe psoriasis vulgaris.
H. Nakagawa (1991)
10.1517/14728214.10.1.35
Emerging drugs for moderate-to-severe psoriasis
M. Magliocco (2005)
10.1016/S0151-9638(05)79222-X
Formes graves de psoriasis : 160 cas
O. Jalal (2005)
10.1111/j.1346-8138.2003.tb00416.x
Efficacy and Safety of Cyclosporine versus Methotrexate in Severe Psoriasis: A Study from North India
K. Sandhu (2003)
10.1001/ARCHDERM.1987.01660350026004
Cyclosporine and male-pattern alopecia.
D. D. Picascia (1987)
10.1016/0190-9622(90)70353-J
Management of patients and side effects during cyclosporine therapy for cutaneous disorders.
M. Fradin (1990)
10.1046/j.1365-4362.1999.00500.x
The role of salicylic acid in the treatment of psoriasis
M. Lebwohl (1999)
10.1111/1523-1747.EP12876222
Mechanisms of cyclosporine A inhibition of antigen-presenting activity in uninvolved and lesional psoriatic epidermis.
K. Cooper (1990)
10.1001/ARCHDERM.1992.01680160070006
Intralesional cyclosporine for psoriasis. Relationship of dose, tissue levels, and efficacy.
M. K. Burns (1992)
10.1016/S0190-9622(89)70339-X
Cyclosporine in dermatology.
A. Gupta (1989)
10.1016/S0190-9622(89)80063-5
Treatment of recalcitrant pyoderma gangrenosum with cyclosporine.
M. Magid (1989)
10.1016/S0190-9622(89)70154-7
Effectiveness of cyclosporine treatment in severe psoriasis: a clinical and immunologic study.
A. Finzi (1989)
10.1093/RHEUMATOLOGY/36.4.433
Testosterone metabolism and cyclosporin A treatment in rheumatoid arthritis.
M. Cutolo (1997)
10.1007/BF02659090
The case for cyclosporin a in psoriatic arthritis
K. Steinsson (2007)
ESTUDIO ABIERTO SOBRE LA SEGURIDAD Y TOLERANCIA DE LA CICLOSPORINA MICROEMULSIONADA EN PACIENTES CON PSORIASIS SEVERA
C. ErikaPáez (1995)
10.1111/j.1365-2133.1990.tb08263.x
The effect of cyclosporin on human epidermal keratinocytes in vitro
P. Dykes (1990)
10.1111/j.1365-2133.1996.tb00707.x
Individualized short‐course cyclosporin therapy in psoriasis
A. Finzi (1996)
10.1001/ARCHDERM.1995.01690190043008
Duration of remission during maintenance cyclosporine therapy for psoriasis. Relationship to maintenance dose and degree of improvement during initial therapy.
C. Ellis (1995)
See more
Semantic Scholar Logo Some data provided by SemanticScholar